Table 1.
Summary of large-scale studies comparing antipsychotic polypharmacy and monotherapy
| Study | Country | Patient no. (APM/APP) | Primary outcome | Results and recommendation |
|---|---|---|---|---|
| Baandrup et al., 2010 | Denmark | 27 633 | Risk of natural death | No increase in the number of concurrently used antipsychotics |
| Katona et al., 2014 | Hungary | 5480/7901 | Time to all-cause treatment discontinuation, mortality, and hospitalization | APM was superior to APP for long-term treatment, considering SGAs in treatment discontinuation. APP was associated with a lower likelihood of mortality and hospitalizations. |
| Kadra et al., 2018 | United Kingdom | 8421/2524 | Mortality | APP effect on mortality was unclear, even after controlling the effect of dose. |
| Tiihonen et al., 2019 | Finland | 62 250 | Rehospitalization | Combining aripiprazole with clozapine was associated with the lowest risk. |
| Kasteridis et al., 2019 | United Kingdom | 17 255 | Unplanned hospitalization and mortality | Results supported APM, and for APP, health care utilization and mortality were not affected. |
Abbreviations: APM, antipsychotic monotherapy; APP, antipsychotic polypharmacy; SGAs, second-generation antipsychotics.